Comparison of Clinical Efficacy between a Single Administration of Long-Acting Gonadotrophin-Releasing Hormone Agonist (GnRHa) and Daily Administrations of Short-Acting GnRHa in In Vitro Fertilization-Embryo Transfer Cycles.
10.3346/jkms.2008.23.4.662
- Author:
Kang Woo CHEON
1
;
Sang Jin SONG
;
Bum Chae CHOI
;
Seung Chul LEE
;
Hong Bok LEE
;
Seung Youn YU
;
Keun Jai YOO
Author Information
1. Laboratory of Reproductive Medicine, Samsung Women's Hospital, Suwon, Korea.
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
In Vitro Fertilization-Embryo Transfer;
Long-Acting GnRHa;
Goserelin;
Recombinant FSH;
Patient's Convenience
- MeSH:
Adult;
Buserelin/*therapeutic use;
*Embryo Transfer;
Female;
*Fertilization in Vitro;
Follicle Stimulating Hormone/therapeutic use;
Goserelin/therapeutic use;
Humans;
Leuprolide/*therapeutic use
- From:Journal of Korean Medical Science
2008;23(4):662-666
- CountryRepublic of Korea
- Language:English
-
Abstract:
This study was aimed to evaluate the efficacy of a single administration of long-acting gonadotrophin-releasing hormone agonist (GnRHa) as compared with daily administrations of short-acting GnRHa in controlled ovarian hyperstimulation (COH) for in vitro fertilization and embryo transfer (IVF-ET) cycles. The mean dosage of recombinant follicle-stimulating hormone (rFSH) required for COH (2,354.5+/-244.2 vs. 2,012.5+/-626.1 IU) and the rFSH dosage per retrieved oocyte (336.7+/-230.4 vs. 292.1+/-540.4 IU) were significantly higher in the long-acting GnRHa group (N= 22) than those in the short-acting GnRHa group (N=28) (p<0.05). However, the mean number of visit to the hospital that was required before ovum pick-up (3.3+/-0.5 vs. 22.2+/-2.0) and the frequency of injecting GnRHa and rFSH (12.8+/-1.2 vs. 33.5+/- 3.5) were significantly decreased in the long-acting GnRHa group (p<0.0001). The clinical pregnancy rate, implantation rate, and early pregnancy loss rate were not significantly different between the 2 groups. So, we suggest that a single administration of long-acting GnRHa is a useful alternative for improving patient's convenience with clinical outcomes comparable to daily administrations of short-acting GnRHa in COH for IVF-ET cycles.
